Your browser doesn't support javascript.
loading
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer, Jens; Köhler, Natalie; Maringer, Yacine; Bucher, Philip; Bilich, Tatjana; Zwick, Melissa; Dicks, Severin; Nelde, Annika; Dubbelaar, Marissa; Scheid, Jonas; Wacker, Marcel; Heitmann, Jonas S; Schroeder, Sarah; Rieth, Jonas; Denk, Monika; Richter, Marion; Klein, Reinhild; Bonzheim, Irina; Luibrand, Julia; Holzer, Ursula; Ebinger, Martin; Brecht, Ines B; Bitzer, Michael; Boerries, Melanie; Feucht, Judith; Salih, Helmut R; Rammensee, Hans-Georg; Hailfinger, Stephan; Walz, Juliane S.
Afiliação
  • Bauer J; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Köhler N; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Maringer Y; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Bucher P; Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.
  • Bilich T; CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.
  • Zwick M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Dicks S; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Nelde A; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Dubbelaar M; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Scheid J; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany.
  • Wacker M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Heitmann JS; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Schroeder S; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Rieth J; Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.
  • Denk M; Faculty of Biology, Albert-Ludwigs-Universität, Freiburg, Germany.
  • Richter M; Faculty of Biology, Albert-Ludwigs-Universität, Freiburg, Germany.
  • Klein R; Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Bonzheim I; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Luibrand J; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Holzer U; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Ebinger M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Brecht IB; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Bitzer M; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Boerries M; Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.
  • Feucht J; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Salih HR; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
  • Rammensee HG; Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany.
  • Hailfinger S; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
  • Walz JS; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Nat Commun ; 13(1): 6401, 2022 10 27.
Article em En | MEDLINE | ID: mdl-36302754
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha